{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(22)"],"submitter":["Zhang ZL"],"pubmed_abstract":["<h4>Background</h4>Coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, first manifested in December 2019, and spread rapidly worldwide. Facing this lethal disease, there is an urgent need to develop potent therapies against SARS-CoV-2 infection. SARS-CoV-2 phylogenetically and symptomatically resembles SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Numerous agents have been utilised during the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) epidemics, which may show some benefit against SARS-CoV-2.<h4>Methods</h4>MEDLINE, EMBASE, Cochrane Library, CBM Disc, China National Knowledge Infrastructure, Wanfang Data, and the China Science and Technology Journal Datab"],"journal":["Annals of translational medicine"],"pagination":["1527"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7729372"],"repository":["biostudies-literature"],"pubmed_title":["Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol."],"pmcid":["PMC7729372"],"pubmed_authors":["Cui M","Zhang ZL","Yu YT","Lin HW","Gu ZC","Gao Y","Zhong H","Liu YX","Le KJ"],"additional_accession":[]},"is_claimable":false,"name":"Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.","description":"<h4>Background</h4>Coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, first manifested in December 2019, and spread rapidly worldwide. Facing this lethal disease, there is an urgent need to develop potent therapies against SARS-CoV-2 infection. SARS-CoV-2 phylogenetically and symptomatically resembles SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Numerous agents have been utilised during the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) epidemics, which may show some benefit against SARS-CoV-2.<h4>Methods</h4>MEDLINE, EMBASE, Cochrane Library, CBM Disc, China National Knowledge Infrastructure, Wanfang Data, and the China Science and Technology Journal Datab","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-04T23:46:28.056Z","creation":"2025-04-04T23:46:28.056Z"},"accession":"S-EPMC7729372","cross_references":{"pubmed":["33313272"],"doi":["10.21037/atm-20-2340"]}}